Novo's Investigational CagriSema, a GLP-1 and Amylin Analog, Demonstrated ~21% Average Weight Loss with Lower Doses in the REDEFINE 9 Trial, Presented at ObesityWeek® 2026 and Published in The Lancet Diabetes & Endocrinology
13 Articles
13 Articles
A recent follow-up study revealed promising results of a new experimental injection of obesity, which demonstrated its ability to help participants lose about 20% of their body weight, even when using low doses, thanks to its combination of active substance in Ozmbek and other anorexic drug. The new drug, called Kagrisema, combines the active substance used in Ozmbek for diabetes treatment, Wigoffi for weight reduction, and Kagrilintaide, an ano…
Ekstra Bladet
After 68 weeks, participants in a new study lost an average of 21 percent of their body weight with Novo's Cagrisema
The Courier-Tribune
Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology
REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity,…
Novo has received positive results from a phase 3 study of the company's next potential super-seller in weight loss medicine, Cagrisema, the company announced in a press release on Saturday evening.
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
